http://www.bing.com/news/search?q=antiulcerant&format=rssSearch resultshttp://www.bing.com/rsslogo.gifhttp://www.bing.com/news/search?q=antiulcerant&format=rssCopyright \xc2\xa9 2026 Microsoft. All rights reserved. These XML results may not be used, reproduced or transmitted in any manner or for any purpose other than rendering Bing results within an RSS aggregator for your personal, non-commercial use. Any other use of these results requires express written permission from Microsoft Corporation. By accessing this web page or using these results in any manner whatsoever, you agree to be bound by the foregoing restrictions.http://www.bing.com/news/apiclick.aspx?ref=FexRss&aid=&tid=69e9a20281c5428fa446e491ee5ae286&url=https%3a%2f%2fmarkets.businessinsider.com%2fnews%2fstocks%2fantiulcerant-drugs-global-markets-to-2022-1025600409&c=9628405653836293447&mkt=en-usLONDON, May 28, 2018 /PRNewswire/ -- Report Scope: This research report categorizes the antiulcerant drugs market by type, including proton pump inhibitors, H2 receptor antagonists, gastric mucosal ...Mon, 28 May 2018 02:00:00 GMTBusiness Insiderhttp://www.bing.com/news/apiclick.aspx?ref=FexRss&aid=&tid=69e9a20281c5428fa446e491ee5ae286&url=https%3a%2f%2fwww.digitaljournal.com%2fpr%2fnews%2fantiulcerant-drugs-market-growth-and-future-prospects-by-forecast-to-2028&c=4607635597060002508&mkt=en-usThe Insight Partners Latest Research for Report “ Antiulcerant Drugs Market Forecast to 2028″ Includes COVID-19 Impact and Global Analysis By Type (Proton pump inhibitors, H2 receptor antagonists, ...Thu, 09 Feb 2023 16:00:00 GMTDigital Journalhttp://www.bing.com/news/apiclick.aspx?ref=FexRss&aid=&tid=69e9a20281c5428fa446e491ee5ae286&url=https%3a%2f%2fpharmatimes.com%2fnews%2fsolvays_pharma_sales_slide_minus_the_antiulcerant_pantoloc_990509%2f&c=5211448385718644407&mkt=en-usShares in Solvay have taken a bashing as the Belgian drugs, chemical and plastics maker posted a disappointing showing for its pharmaceuticals division in the first half of the year. Shares in Solvay ...Sun, 29 Jul 2007 17:00:00 GMTPharmaTimeshttp://www.bing.com/news/apiclick.aspx?ref=FexRss&aid=&tid=69e9a20281c5428fa446e491ee5ae286&url=https%3a%2f%2fpharmatimes.com%2fnews%2ffda_rejects_astrazenecas_nexiumaspirin_combo_983158%2f&c=3609988774824718555&mkt=en-usAstraZeneca' has received some bad news after regulators in the USA requested more information on two filings the company has made to get more expanded approvals for its antiulcerant blockbuster ...Mon, 31 May 2010 17:00:00 GMTPharmaTimes